Abstract |
The absorption of YJA-20379-8 (3-butyryl-4-[5-(R)-(+)-methylbenzylamino]-8-ethoxy-1,7-naphthyrid ine) from various rat gastrointestinal segments was evaluated using in-situ closed-loops. The pharmacokinetics of the drug were also evaluated after oral administration to rats with acetic acid-induced gastric ulcer (AIURs). The concentrations of YJA-20379-8 in the biological samples were analyzed by HPLC. The absorption of YJA-20379-8 from stomach and jejunum was fast, but approximately 50% of the drug was recovered from each segment at 24 h. The total areas under the plasma concentration-time curves from time zero to 24h (AUC(0-24h)) were 161, 392, 233, 365, and 226 microg min mL(-1) for stomach, duodenum, jejunum, ileum, and colon, respectively. After oral administration of the drug, the plasma concentrations and the resultant AUC (0- 12h) were not significantly different between control and AIURs. The detection limits of YJA-20379-8 in human plasma and urine were 50 and 100 ng mL(-1), respectively. The results suggest that modification of the oral dose of YJA-20379-8 may not be required in gastric ulcer patients if the present rat pharmacokinetic data could be extrapolated to man.
|
Authors | S Y Chung, K S Han, H J Kim, J Kim, M S Chang, M G Lee |
Journal | The Journal of pharmacy and pharmacology
(J Pharm Pharmacol)
Vol. 51
Issue 9
Pg. 1025-30
(Sep 1999)
ISSN: 0022-3573 [Print] England |
PMID | 10528985
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 3-butyryl-4-(5R-methylbenzylamino)-8-ethoxy-1,7-naphthyridine
- Anti-Ulcer Agents
- Naphthyridines
- Acetic Acid
|
Topics |
- Acetic Acid
- Administration, Oral
- Animals
- Anti-Ulcer Agents
(administration & dosage, pharmacokinetics, therapeutic use)
- Area Under Curve
- Chromatography, High Pressure Liquid
- Intestinal Absorption
- Male
- Naphthyridines
(administration & dosage, pharmacokinetics, therapeutic use)
- Rats
- Rats, Sprague-Dawley
- Stomach Ulcer
(chemically induced, drug therapy, metabolism)
|